Choroidal Neovascular Membranes Medication

Updated: Mar 01, 2017
  • Author: Steve Charles, MD; Chief Editor: Andrew A Dahl, MD, FACS  more...
  • Print

Anti-VEGF therapy

Class Summary

Reduces risk of visual loss similar to that seen with photodynamic therapy.

Pegaptanib (Macugen)

A selective VEGF antagonist that promotes vision stability and reduces visual acuity loss and progression to legal blindness. VEGF causes angiogenesis and increases vascular permeability and inflammation, all of which contribute to neovascularization in age-related wet macular degeneration. Macugen is much less effective than bevacizumab, aflibercept, or ranibizumab.